Daiichi Sankyo Partners with Tempus AI – Foundation Models Target ADC Biomarker Discovery and Patient Stratification
Daiichi Sankyo Co., Ltd. (TYO: 4568) announced a strategic partnership with Tempus AI, Inc., a...
Daiichi Sankyo Co., Ltd. (TYO: 4568) announced a strategic partnership with Tempus AI, Inc., a...
Germany-based pharmaceutical major Boehringer Ingelheim has entered into a multi-year strategic collaboration with Tempus (NASDAQ:...
UK pharmaceutical leader AstraZeneca (AZ, NASDAQ: AZN) has expanded its collaboration with US-based Tempus AI,...
US major Illumina (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM) are joining forces to...